People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| SRT Therapeutics, Inc. | — | Biotechnology | Series C | $47.4M | $316.4M | 2025 |
| Evida Biosciences Inc. | — | Biotechnology | Series C | $42.0M | $365.0M | 2024 |
Rolf Benirschke at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rolf Benirschke on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Walsh | 2 | 24 |
| Lauren Otsuki | 2 | 4 |
| Shierley Widjaja | 2 | 3 |
| Brian G. Feagan, M.D. | 2 | 2 |
| Scott Glenn | 1 | 4 |
| Ed Prunchunas | 1 | 1 |
| David Wrigley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.